FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808861424> ?p ?o ?g. }

• W2808861424 endingPage "v36" @default.
• W2808861424 startingPage "v36" @default.
• W2808861424 abstract "Introduction: The accumulation of a multitude of subtle molecular aberrations during tumor progression limit the efficacy of anti-cancer drugs. A vast array of these variations can be assessed with Poly-Ligand Profiling (PLP), which is utilizing libraries of trillion unique ssDNA with aptamer binding properties. The aims of this study were to develop a PLP library that differentiate pancreatic cancer patients who can benefit from gemcitabine+evofosfamide (GE) or gemcitabine+placebo (G) and identify its molecular targets. Methods: Patients: locally advanced or metastatic pancreatic cancer patients randomized to G vs GE in the unsuccessful phase III MAESTRO trial (Threshold Pharmaceuticals, Merck KgaA). FFPE tissues of patients with good (OS > 13 mos) or poor (OS < 7 mos) outcome from GE were used for PLP library development. Affinity maturation and testing of library for binding FFPE tissue is done with IHC-like protocol. Assay conditions and algorithm were locked based on the training set (n = 12) and used for testing assay performance in the blinded set (n = 172, primary and metastatic sites). PLP-assay performance metrics from blinded test set served to estimate the impact on the MAESTRO study (n = 693) by performing 1000 simulations. For target ID, FFPE tissue of patients with poor outcome, stained with enriched library, was recovered, lysed, underwent affinity-based pull-downs, purified with PAGE gel and subjected to high resolution mass-spectrometry (MS). Results: 1,000 simulations of projected PLP-positive patients from MAESTRO study revealed a median OS increase of 37.6% (mean) in G+E cohort, compared to G (17.4% OS increase in MAESTRO) with mean Hazard Ratio (HR) 0.72 (0.84 in MAESTRO). 96.9% of simulated trials achieved statistical significance. For primary tumor samples the median OS increase for G+E patients was 53.4% with mean HRs of 0.64 with 100% of trials exhibiting log-rank p < 0.05. MS reliably detected 20 proteins, 11 of which have reported associations with pancreatic cancer and 6 have been associated with resistance to gemcitabine: vimentin (VIM), pyruvate kinase (PKM), endoplasmic reticulum chaperone BiP (HSPA5), heat shock protein HSP 90-alpha (HSP90AA1), Histone H3-1 (HIST1H3A), heat shock protein beta-1 (HSPB1). Vimentin is a mesenchymal marker whose expression increases during epithelial–to-mesenchymal transition (EMT) and tumor progression. EMT results in the suppression of human equilibrative/concentrative nucleoside transporter and protects tumor cells from gemcitabine. GRP78 overexpression confers resistance to gemcitabine and its knockdown sensitizes tumor cells to drug treatment. Alternative splicing of PKM promotes gemcitabine resistance in pancreatic cancer cells most likely by boosting glycolysis-fueled proliferation. Heat shock proteins regulate multiple tumor survival and progression pathways and their inhibition attenuates resistance of cancer cells to gemcitabine. Pancreatic tumors demonstrate increased histones acetylation, which was correlating with increased protection against gemcitabine. Further characterization of these candidate targets is ongoing. Conclusion: PLP is a novel platform for classifying pancreatic cancer patients according to their benefiting from GE treatment. MS of the PLP library pull-downs reveals targets associated with gemcitabine resistance. In principle, the novel PLP platform could be applied to different therapeutic regimen for the development of urgently needed companion diagnostic tests in cancer and other diseases." @default.
• W2808861424 created "2018-06-29" @default.
• W2808861424 creator A5010337583 @default.
• W2808861424 creator A5015295914 @default.
• W2808861424 creator A5017973561 @default.
• W2808861424 creator A5018601611 @default.
• W2808861424 creator A5020379737 @default.
• W2808861424 creator A5020497405 @default.
• W2808861424 creator A5037644603 @default.
• W2808861424 creator A5041783466 @default.
• W2808861424 creator A5042870042 @default.
• W2808861424 creator A5048365667 @default.
• W2808861424 creator A5051130911 @default.
• W2808861424 creator A5055435399 @default.
• W2808861424 creator A5063322984 @default.
• W2808861424 creator A5073571977 @default.
• W2808861424 creator A5075546945 @default.
• W2808861424 creator A5082951042 @default.
• W2808861424 creator A5089958593 @default.
• W2808861424 date "2018-06-01" @default.
• W2808861424 modified "2023-10-02" @default.
• W2808861424 title "Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets" @default.
• W2808861424 doi "https://doi.org/10.1093/annonc/mdy151.131" @default.
• W2808861424 hasPublicationYear "2018" @default.
• W2808861424 type Work @default.
• W2808861424 sameAs 2808861424 @default.
• W2808861424 citedByCount "6" @default.
• W2808861424 countsByYear W28088614242018 @default.
• W2808861424 countsByYear W28088614242019 @default.
• W2808861424 countsByYear W28088614242021 @default.
• W2808861424 countsByYear W28088614242022 @default.
• W2808861424 countsByYear W28088614242023 @default.
• W2808861424 crossrefType "journal-article" @default.
• W2808861424 hasAuthorship W2808861424A5010337583 @default.
• W2808861424 hasAuthorship W2808861424A5015295914 @default.
• W2808861424 hasAuthorship W2808861424A5017973561 @default.
• W2808861424 hasAuthorship W2808861424A5018601611 @default.
• W2808861424 hasAuthorship W2808861424A5020379737 @default.
• W2808861424 hasAuthorship W2808861424A5020497405 @default.
• W2808861424 hasAuthorship W2808861424A5037644603 @default.
• W2808861424 hasAuthorship W2808861424A5041783466 @default.
• W2808861424 hasAuthorship W2808861424A5042870042 @default.
• W2808861424 hasAuthorship W2808861424A5048365667 @default.
• W2808861424 hasAuthorship W2808861424A5051130911 @default.
• W2808861424 hasAuthorship W2808861424A5055435399 @default.
• W2808861424 hasAuthorship W2808861424A5063322984 @default.
• W2808861424 hasAuthorship W2808861424A5073571977 @default.
• W2808861424 hasAuthorship W2808861424A5075546945 @default.
• W2808861424 hasAuthorship W2808861424A5082951042 @default.
• W2808861424 hasAuthorship W2808861424A5089958593 @default.
• W2808861424 hasBestOaLocation W28088614241 @default.
• W2808861424 hasConcept C121608353 @default.
• W2808861424 hasConcept C126322002 @default.
• W2808861424 hasConcept C143998085 @default.
• W2808861424 hasConcept C2780210213 @default.
• W2808861424 hasConcept C2780258809 @default.
• W2808861424 hasConcept C502942594 @default.
• W2808861424 hasConcept C70721500 @default.
• W2808861424 hasConcept C71924100 @default.
• W2808861424 hasConcept C86803240 @default.
• W2808861424 hasConceptScore W2808861424C121608353 @default.
• W2808861424 hasConceptScore W2808861424C126322002 @default.
• W2808861424 hasConceptScore W2808861424C143998085 @default.
• W2808861424 hasConceptScore W2808861424C2780210213 @default.
• W2808861424 hasConceptScore W2808861424C2780258809 @default.
• W2808861424 hasConceptScore W2808861424C502942594 @default.
• W2808861424 hasConceptScore W2808861424C70721500 @default.
• W2808861424 hasConceptScore W2808861424C71924100 @default.
• W2808861424 hasConceptScore W2808861424C86803240 @default.
• W2808861424 hasLocation W28088614241 @default.
• W2808861424 hasOpenAccess W2808861424 @default.
• W2808861424 hasPrimaryLocation W28088614241 @default.
• W2808861424 hasRelatedWork W114644245 @default.
• W2808861424 hasRelatedWork W1964744725 @default.
• W2808861424 hasRelatedWork W1969578744 @default.
• W2808861424 hasRelatedWork W1995076802 @default.
• W2808861424 hasRelatedWork W2005537476 @default.
• W2808861424 hasRelatedWork W2089179463 @default.
• W2808861424 hasRelatedWork W2319496893 @default.
• W2808861424 hasRelatedWork W2376347278 @default.
• W2808861424 hasRelatedWork W2973816194 @default.
• W2808861424 hasRelatedWork W4311308018 @default.
• W2808861424 hasVolume "29" @default.
• W2808861424 isParatext "false" @default.
• W2808861424 isRetracted "false" @default.
• W2808861424 magId "2808861424" @default.
• W2808861424 workType "article" @default.